What are the standard deliverables produced by a HEOR function?

Common HEOR deliverables include the Global Value Dossier used across multiple markets, AMCP Format submissions built for US health plans following the AMCP Format for Formulary Submissions, and country-specific health technology assessment submissions to bodies such as NICE, CADTH, IQWiG, or HAS, each with its own methodological expectations. Because these bodies apply different reference cases, a single global dossier typically must be adapted rather than reused unchanged across markets.

Why should HEOR planning start before pivotal trial design rather than after FDA clearance?

If pivotal trial endpoints, comparator selection, and follow-up duration are chosen solely to satisfy regulatory requirements, the resulting dataset frequently cannot support the cost-effectiveness or budget impact claims needed for payer coverage, forcing companies into costly post-market evidence generation. Increasingly, mature HEOR functions engage during Phase 1 or early feasibility work to ensure the eventual pivotal trial can serve both regulatory and value-demonstration purposes.

Which methodological standards govern HEOR analyses that payers will accept?

Widely referenced methodological standards include ISPOR's Good Practices guidance, the AMCP Format for Formulary Submissions (version 4.1), the NICE Reference Case in the UK, and the ICER Value Assessment Framework in the US commercial context, each specifying acceptable modeling approaches, discounting rates, and evidence hierarchies. CMS's Transitional Coverage for Emerging Technologies (TCET) program has also begun explicitly referencing HEOR-aligned evidence expectations, reinforcing that these standards now extend into US federal coverage policy as well.

All terms

ReimbursementClinical Evidence Hospital Buyer & ReimbursementHEOR

Health Economics and Outcomes Research

Research discipline that generates economic, clinical, and patient-reported evidence to support payer access, HTA submissions, and value demonstration.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

Health Economics and Outcomes Research (HEOR) is the multidisciplinary field that generates economic models (cost-effectiveness, cost-utility, budget impact), real-world evidence, and patient-reported outcomes data used by payers, HTA bodies, and health systems to assess a technology's value. HEOR deliverables include the Global Value Dossier, AMCP Format submissions to US health plans, and country-specific HTA submissions (NICE, CADTH, IQWiG, HAS).

What the regulation says

Methodology references: ISPOR Good Practices, AMCP Format for Formulary Submissions v4.1, NICE Reference Case, ICER Value Assessment Framework. CMS's TCET program explicitly requires evidence aligned with HEOR principles.

What this means in practice

Strong HEOR is the difference between coverage and non-coverage in single-payer systems and is rising in importance for US commercial payers. Increasingly, HEOR planning starts at preclinical/early clinical to ensure trial endpoints support the value story.

Examples

A MedTech company developed a novel diagnostic device and used HEOR to demonstrate its cost-effectiveness compared to existing methods, helping secure a positive reimbursement decision from a national health technology assessment body.
Prior to launching a new surgical implant, the manufacturer conducted HEOR studies to generate real-world evidence on patient-reported outcomes and long-term cost savings, which were then included in their AMCP dossier for US commercial payers.
Early HEOR planning for a therapeutic device led to the inclusion of specific quality of life endpoints in clinical trials, ensuring the generated data would support the value proposition for future payer negotiations.

Common pitfalls

•Designing pivotal trials around regulatory endpoints only and finding the dataset can't support the HEOR case.
•Treating HEOR as a post-launch activity instead of an evidence-generation strategy from Phase 1.

Frequently asked questions

HEOR generates economic models such as cost-effectiveness and budget impact analyses, real-world evidence, and patient-reported outcomes data intended to answer payer and health technology assessment questions about value, whereas FDA submissions focus on demonstrating safety and effectiveness against a regulatory standard. A pivotal trial can satisfy FDA's evidentiary bar while still lacking the endpoints, comparator arms, or follow-up duration that a payer's HEOR-based coverage decision requires.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Reimbursement

Budget Impact Model(BIM)

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

Reimbursement

Health Technology Assessment(HTA)

Systematic evaluation of clinical and economic value of a health technology.

Reimbursement

Incremental Cost-Effectiveness Ratio(ICER)

Cost per additional unit of health outcome (often QALY) versus comparator.

Reimbursement

Quality-Adjusted Life Year(QALY)

Outcome metric combining length and quality of life used in HTA.

More in Reimbursement

· Same category

Reimbursement

RWE for Reimbursement

Real-world evidence used to support coverage and payment decisions.

Reimbursement

340B Drug Pricing Program(340B)

Federal program providing discounted drugs to safety-net providers.

Reimbursement

Ambulatory Payment Classification(APC)

The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.

Reimbursement

ASC Site-of-Service Shift

Migration of procedures from hospitals to ambulatory surgery centers.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (2)

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Official citation replacements checked: 2026-11-01. Medicare documents support Medicare coding, coverage or payment context, not every payer policy or CPT editorial procedure. Citation replacement does not change the full term review date.

Tier 3Peer-reviewed and registry evidence· 3

Link health: 3 verified· last checked 2026-06-20· added official documents checked 2026-11-01

ISPOR·1AMCP·1NICE·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Reimbursement0 / 37

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Reimbursement
Acronym: HEOR
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Research discipline that generates economic, clinical, and patient-reported evidence to support payer access, HTA submissions, and value demonstration.

·Strong HEOR is the difference between coverage and non-coverage in single-payer systems and is rising in importance for US commercial payers.
·Increasingly, HEOR planning starts at preclinical/early clinical to ensure trial endpoints support the value story.
·HEOR deliverables include the Global Value Dossier, AMCP Format submissions to US health plans, and country-specific HTA submissions (NICE, CADTH, IQWiG, HAS).

Remember this

Watch out: Designing pivotal trials around regulatory endpoints only and finding the dataset can't support the HEOR case.

Related terms

You may also need

Auto-suggested from Reimbursement and shared keywords.

All Reimbursement terms